about
Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasisEffect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology.FUT2 genotype influences lung function, exacerbation frequency and airway microbiota in non-CF bronchiectasis.Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial.Intestinal Microbiota Composition in Sudden Infant Death Syndrome and Age-Matched Controls.Infection's Sweet Tooth: How Glycans Mediate Infection and Disease Susceptibility.Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis.Understanding the impact of antibiotic therapies on the respiratory tract resistome: a novel pooled-template metagenomic sequencing strategyThe contribution of respiratory microbiome analysis to a treatable traits model of carePPARγ is reduced in the airways of non-CF bronchiectasis subjects and is inversely correlated with the presence of Pseudomonas aeruginosaTotal bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosisLong-Term Azithromycin Reduces Haemophilus influenzae and Increases Antibiotic Resistance in Severe AsthmaLong-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysisThe impact of CFTR modulator therapies on CF airway microbiologyAirway abundance of Haemophilus influenzae predicts response to azithromycin in adults with persistent uncontrolled asthma
P50
Q28256930-E5DC6BC1-B3E4-4133-9606-9553765A04D5Q38688984-431EB103-C335-4DE7-A100-D91143200230Q38799650-52454990-25D4-4A73-9C06-1E5BF0CD63D8Q40583472-BDD6CF81-048B-4896-9311-84CBD8F93FC1Q40597951-54B035DF-D352-4137-A175-36A81B86DD50Q46254685-5C36160C-3DBB-4959-935E-510185AB2478Q47597465-16C24197-E0A3-458D-A18C-3B9882397129Q52579711-8F1143F0-816A-4206-AAA8-E0A6EEA77589Q56523707-F913ACFD-BCBA-4C4E-8015-1CA0C1D11A13Q57041458-30431EA9-106B-4681-9949-25657BA99301Q58775115-2F5381C4-4F2A-4190-9425-EA4060F002ECQ90565760-5FA821C2-214E-4FE9-8980-FF53B8E4C433Q92388296-2B6A6744-6A10-4671-9BDB-50604C6039F5Q92575426-9631A497-ABE7-43A2-8261-322AA505C6A1Q92645599-5DD7ED18-6DF7-4D6D-8B4E-3EF43D0AA059Q94518793-1CDBB3A0-83A9-4BA1-8017-5588A7B940E8
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Steven L Taylor
@en
Steven L Taylor
@nl
type
label
Steven L Taylor
@en
Steven L Taylor
@nl
prefLabel
Steven L Taylor
@en
Steven L Taylor
@nl
P31
P496
0000-0003-4357-8243